07.25.13
Bristol-Myers Squibb
2Q Revenues: $4.0 billion (-9%)
2Q Earnings: $536 million (-17%)
YTD Revenues: $7.9 billion (-19%)
YTD Earnings: $1.1 billion (-34%)
Comments: U.S. sales decreased 22% to $2.0 billion in the quarter and international sales increased 10% to $2.0 billion. Due to continued generic erosion, Abilify sales declined 21% to $563 million in the quarter, Plavix sales dropped 94% to $44 million, and Avapro/Avalide sales were down 52% to $56 million. Baraclude sales were $371 million, up 4%. Reyataz sales were $431 million, up 6%. Sustiva Franchise sales were up 6% to $411 million. Sprycel sales were up 28% to $312 million. Yervoy sales were up 44% to $233 million.
2Q Revenues: $4.0 billion (-9%)
2Q Earnings: $536 million (-17%)
YTD Revenues: $7.9 billion (-19%)
YTD Earnings: $1.1 billion (-34%)
Comments: U.S. sales decreased 22% to $2.0 billion in the quarter and international sales increased 10% to $2.0 billion. Due to continued generic erosion, Abilify sales declined 21% to $563 million in the quarter, Plavix sales dropped 94% to $44 million, and Avapro/Avalide sales were down 52% to $56 million. Baraclude sales were $371 million, up 4%. Reyataz sales were $431 million, up 6%. Sustiva Franchise sales were up 6% to $411 million. Sprycel sales were up 28% to $312 million. Yervoy sales were up 44% to $233 million.